ReachMD

Dr. Fudin graduated from Albany College of Pharmacy & Health Sciences with his bachelor’s degree and Pharm.D. He completed an Oncology/Hematology fellowship at SUNY/Upstate Medical Center. He is a Diplomate to the Academy of Integrative Pain Management and a Fellow to the American College of Clinical Pharmacy, the American Society of Health-system Pharmacists, and the Federation of State Medical Board. Dr. Fudin is a Section Editor for Pain Medicine, Co-Editor-At-Large for Practical Pain Management, Founder/Chairman of Professionals for Rational Opioid Monitoring & Pharmacotherapy, and peer reviewer for several professional journals. He has participated in developing practice guidelines for use of opioids in chronic noncancer pain (APS, AAPM collaborative) and participated in national (US Health and Human Services) and international guideline development for various pain types including but not limited to arthritis, fibromyalgia, and palliative care. He has also participated in the development and co-authored consensus guidelines for the treatment of opioid-induced constipation and for urine drug monitoring. He practices as a Clinical Pharmacy Specialist and Director, PGY-2 Pharmacy Pain Residency Programs at the Stratton Veterans Administration Medical Center in Albany NY. He holds adjunct faculty positions at Western New England University College of Pharmacy in Springfield MA and Albany College of Pharmacy & Health Sciences. Dr. Fudin has been an invited speaker on pain management nationally and internationally. Dr. Fudin is a Founder and Board of Trustee for the Society of Palliative Care Pharmacists where he serves on several committees. He is a member of several professional organizations and is appointed as a Board Member to the New York State Office of Professional Medical Conduct. He is owner and managing editor for paindr.com and Founder and CEO of Remitigate LLC, a software development company that has launched an application to help clinicians interpret urine drugs screens (Urintel) and another that interprets risk of opioid-induced respiratory depression and guides clinicians in qualifying patients for in-home naloxone. There are several pipeline products including a pharmacogenetic and opioid taper applications plus other opioid safety software initiatives in development. He is also the Founder of Pharmacist Consulting Services (DBA Remitigate Therapeutics), a virtual patient consultation service that uses technology platforms to guide clinicians towards viable medication options and recommended approaches when complex pharmacotherapeutic issues and dilemmas arise which might otherwise limit successful patient outcomes. Dr. Fudin is a prolific lecturer, writer, editor, and teacher, and researcher, with over 350 publications on pain management topics.